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Objectives. We investigated the long-term prognosis of com-
pletely asymptomatic adult patients with hypertrophic cardiomy-
opathy (HC). Diagnosis of HC was suspected because of an
abnormal electrocardiogram and/or cardiac murmur and con-
firmed by echocardiography and/or left ventricular angiography,
and hemodynamic investigation.
Background. Hypertrophic cardiomyopathy shows marked het-
erogeneity in clinical expression and prognosis. The prognosis of
asymptomatic patients with HC has not been fully defined.
Methods. Of 128 consecutive adult patients with HC, 58 asymp-
tomatic patients (Group 1, mean age 42.8 years) and 70 symp-
tomatic patients (Group 2, mean age 50.4 years) were studied to
assess cardiac mortality. Mean follow-up periods were 11.0 years
for Group 1 and 9.1 years for Group 2.
Results. At presentation, Group 1 patients were younger and
had smaller left atrial dimensions than did Group 2 patients. The
annual cardiac mortality rate and the rate for sudden death alone
in Group 1 were significantly lower than in Group 2 (0.9% vs.
1.9%, p < 0.05, 0.1% vs. 1.4%, p < 0.05, respectively). Although
about one-third of the survivors in Group 1 had cardiac symptoms
at their most recent evaluation, only one patient died suddenly
compared with eight in Group 2. The annual mortality rate due to
heart failure was similar in each group. Only a syncopal episode
was associated with both cardiac death and sudden death for both
groups combined.
Conclusions. The cardiac mortality rate for completely asymp-
tomatic adult patients with HC was very low, significantly lower
than that of symptomatic patients, and there was a disproportion-
ately low incidence of sudden death.
(J Am Coll Cardiol 1999;33:206–11)
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Earlier hospital-based clinical investigations of hypertrophic
cardiomyopathy (HC) reported a high incidence of serious
ventricular arrhythmias, sudden death, and overall annual
mortality rates between 2% and 4% (1–11). In contrast, recent
outpatient population or community-based studies have re-
ported a favorable clinical course and prognosis (12–16). The
diversity of clinical expression and prognosis in HC have
become well known. It is, therefore, necessary to recognize all
subsets of patients within the broad disease spectrum of HC
for a more realistic clinical perspective.
See page 218
Although some patients with HC may be severely symptom-
atic or require surgical treatment (17–19), many remain
asymptomatic and unaware of their disease for years. In such
patients, the diagnosis of HC is often first made in the course
of routine examinations, and their disease process and long-
term outcomes are not well defined. Consequently, we inves-
tigated the clinical features and long-term outcomes in a
relatively large group of adult patients who had HC but no
cardiac symptoms. They were all diagnosed because of an
abnormal electrocardiogram (ECG) and/or cardiac murmur
identified at the time of routine health examinations or during
evaluation of noncardiac problems.
Methods
Selection of patients. In Japan, annual health examinations
of students and workers, including an ECG, are part of the
health care system. In addition, the ECG is often used as a
routine screening test for patients with symptoms not neces-
sarily limited to cardiac symptoms to exclude cardiovascular
abnormalities. A considerable number of asymptomatic pa-
tients with HC are therefore identified initially at local general
hospitals owing to a cardiac murmur or an abnormal ECG.
Because of our interest in HC, we have vigorously evaluated
patients with HC using cardiac catheterization for accurate
diagnosis and further investigations, and have followed even
asymptomatic patients meticulously. The vast majority of our
patients have been specifically referred from outlying hospitals
with an established diagnosis of HC for cardiac catheterization,
advice, and advanced care because of the known interest of our
institution in HC.
One hundred and fifty-two patients with HC were admitted
to our institution for cardiac catheterization from August 1968
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to May 1994. Eighteen patients were excluded because of 1)
young age (,20 years) at diagnosis (n 5 3); 2) severe mitral
regurgitation associated with ruptured mitral valve chordae
(n 5 1); 3) coronary artery disease with stenosis $75% in
major coronary arteries on coronary angiography (n 5 4); or 4)
apical hypertrophy (n 5 10). Apical hypertrophy was defined
as the presence of a spadelike configuration of the left ventricle
(LV) at diastole demonstrated by LV angiography, with a septal
thickness #15 mm by echocardiography and/or LV angiography
(20). Only six patients (3.9%) were lost to follow-up. Thus, the
final study cohort consisted of 128 adult patients with HC.
All patients were followed until death or for a minimum of
1 year. The mean follow-up time was 9.9 years (range 5 months
to 27 years). There were 112 men and 16 women aged 20 to 74
years (mean 47 years). Of the 128 patients with HC, 58
completely asymptomatic patients (Group 1) were identified
and represent the focus of the present study. The remaining 70
patients (Group 2) had at least one of the following cardiac
symptoms: cardiovascular functional limitation (New York
Heart Association [NYHA] functional class $II) (n 5 27),
chest pain (n 5 19), palpitations (n 5 19), or a syncopal
episode ,1 year before presentation (n 5 8). None of the
patients were in NYHA functional class IV. None were
included solely on the basis of a diagnosis made during a
systematic pedigree analysis. Of the 128 patients, 124 were
from separate pedigrees and completely unrelated. The re-
maining four patients were from two families, both of which
contributed two patients to the cohort.
The diagnosis of HC was based on echocardiographic and
LV angiographic identification of a hypertrophied, nondilated
LV with normal systolic function (LV ejection fraction by LV
angiography .0.5), and the absence of another cardiac or
systemic disease capable of producing the magnitude of LV
hypertrophy present in the patient (21,22). Because 10 patients
were presented before echocardiography was introduced into
our clinical practice in 1974, the diagnosis of HC was made
from the clinical, ECG, hemodynamic, and angiographic find-
ings (2,4,5,23). In seven of these patients the diagnosis was
subsequently confirmed by echocardiography (22). Patients
with a history of hypertension were included in the study. In
the vast majority of cases, the hypertension was mild or well
controlled with therapy, and was clearly disproportionate to
the degree of LV hypertrophy observed by echocardiography.
Clinical examination. At the time of admission, clinical
characteristics including age, family history of HC or sudden
death, cardiac symptoms, and NYHA functional class were
recorded. Physical examination, 12-lead ECG, and baseline
laboratory studies were performed, including left and right
cardiac catheterization, LV and coronary angiography,
M-mode echocardiogram, 2-dimensional echocardiography,
and 24-h Holter ECG when possible.
Cardiac catheterization. All patients underwent right and
left heart catheterization and LV and coronary angiography.
Hemodynamic data judged suitable for quantitative analysis
were available in 118 (92%) patients. Patients were considered
to have an LV outflow obstruction if the pressure gradients
measured under basal conditions or with provocation (with
isoproterenol infusion, premature ventricular contractions, or
the Valsalva maneuver) were greater than 30 mm Hg. Cardiac
output was determined by thermodilution. The LV ejection
fractions were calculated from the cineangiograms by the
area-length method (24). We received informed consent from
all patients before cardiac catheterization.
Echocardiography. Echocardiographic studies were per-
formed in 118 (92%) patients at presentation using commer-
cially available instruments. Echocardiographic data judged
suitable for quantitative analysis was available in 113 (88%)
patients, and the following measurements were recorded for
each patient: diastolic ventricular septal and posterior wall
thickness, indexed LV cavity dimensions during systole and
diastole, and indexed left atrial (LA) dimensions (25).
Electrocardiography. The 12-lead ECG recorded at pre-
sentation was evaluated for rhythm disturbances and conduc-
tion disease including atrioventricular block and intraventric-
ular conduction delay. The Sokolow-Lyon index was used as a
measure of LV hypertrophy (26). A 24-h Holter ECG was
obtained in 84 (66%) patients in similar proportions in both
groups. Supraventricular or ventricular tachycardia was de-
fined as three or more premature complexes in succession.
Medications. In the present study, patients were generally
given medical therapy in a systematic and consistent fashion.
Medical therapy was directed toward control of symptoms,
arrhythmias, outflow obstruction, coexisting hypertension, and
prevention of peripheral embolization. Patients with angina
pectoris were treated with beta-adrenergic blocking agents
(usually propranolol, 30 to 120 mg/day) if obstruction was
present, or with calcium channel blockers (usually verapamil,
120 to 240 mg/day) if absent. Patients with severe congestive
symptoms received diuretic agents (e.g., furosemide, thiazides)
or an angiotensin-converting enzyme inhibitor (captopril) if
obstruction was absent. None received amiodarone. Group 1
patients did not receive drug treatment unless there was
coexisting hypertension, cardiac symptoms developing during
the follow-up period, or additional clinical variables regarded
as risk factors of unexpected sudden death, such as an unfa-
vorable family history or the presence of ventricular tachycar-
dia. Some Group 2 patients did not receive treatment because
they exhibited only mild symptoms, showed poor compliance,
or their condition improved during the follow-up period.
Because of the long time span of the study and the relatively
rare occurrence of HC, randomization was not performed. As
few patients were severely symptomatic with poor response to
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medical therapy, no myectomies for the surgical relief of
obstruction were performed.
Follow-up. Initial clinical presentation was defined as the
time when the diagnostic cardiac catheterization was per-
formed at our institution. The most recent clinical assessments
were obtained during May 1995. Clinical details and follow-up
were obtained by reviewing each subject’s complete (inpatient
and outpatient) medical records and mail contact, or by
telephone contact when necessary. However, reliable informa-
tion regarding the HC-related symptoms at the most recent
clinical evaluation was not available for all the patients who
died in each group as well as for 1 survivor in Group 2 who
experienced a cerebral vascular accident. In cases of death, the
cause was obtained from the death certificate, autopsy when
available, or by questioning the relatives or physicians involved
in the patient’s care. Cardiac death was defined as sudden
death or congestive heart failure death. Sudden death was
assumed to be cardiac, and was defined as a witnessed death
within 1 h after the onset of symptoms or an unwitnessed death
in a subject known to be alive and functioning normally 24 h
before death (27). Unexpected cardiovascular collapse occur-
ring unexpectedly in the context of severe congestive heart
failure was regarded as heart failure death rather than as
sudden death.
Statistical analysis. Data were expressed as mean 6 SD.
Statistical analyses were performed on a Macintosh LC 630
computer using the Stat View 4.11 application package and the
Survival Tool 1.11 plug-in application. Differences between
continuous variables were determined using the unpaired t
test. Differences between proportions were determined using
the chi-square test or the Fisher exact test, as appropriate. The
annual mortality rate was calculated according to the Kaplan-
Meier method (28). Comparison of survival curves between
Group 1 and Group 2 was made using the log-rank test. To
assess the risk factors for cardiac death and for sudden death,
univariate analysis was performed using the Cox regression
model for both groups combined.
Results
Baseline clinical characteristics. In all the Group 1 pa-
tients, the initial reason for diagnosis of HC was an abnormal
ECG and/or cardiac murmur. These were identified during
evaluation of noncardiac problems in approximately one-half
of the patients (n 5 30), and at the time of a routine health
examination in the other half (n 5 28). In contrast, most of the
Group 2 patients were diagnosed because of cardiac symptoms
(n 5 60). The remaining 10 patients were diagnosed because of
an abnormal ECG and/or cardiac murmur identified at the
time of a routine health examination (n 5 6) or during
evaluation of noncardiac problems (n 5 4).
Group 1 patients were younger (p , 0.01) and showed a
higher percentage of men (p , 0.05) than did Group 2. There
were similar frequencies of patients with coexisting hyperten-
sion and of patients with a family history of HC or sudden death
in each group. Table 1 gives details on baseline clinical features.
Group 2 had significantly larger indexed LA dimensions
(p , 0.05) than did Group 1; ECG, hemodynamic, and 24-h
Holter ECG data were similar in each group. There was no
sustained (.30 s) ventricular tachycardia in either group.
Table 2 provides more ECG, hemodynamic, echocardio-
graphic, and 24-h Holter ECG data.
Long-term follow-up. Survival. During follow-up, there
were 3 cardiac deaths and 2 noncardiac deaths in Group 1, and
11 cardiac deaths and 6 noncardiac deaths in Group 2.
Regarding the modes of cardiac death, only one patient in
Group 1 died suddenly compared with eight in Group 2. Two
patients in Group 1 died of congestive heart failure versus
three in Group 2. The annual cardiac mortality rate was 0.9%
in Group 1 and 1.9% in Group 2 (Fig. 1). The annual mortality
rate confined to sudden death was only 0.1% in Group 1 and
1.4% in Group 2 (Fig. 2). The annual cardiac mortality rate
and the rate for sudden death alone in Group 1 were signifi-
cantly lower than in Group 2 (p , 0.05, p , 0.05, respectively).
The annual mortality rate due to heart failure was similar in
both groups.
Clinical, ECG, hemodynamic, echocardiographic, and 24-h
Holter ECG variables were examined for an association with
decreased survival during the follow-up period for both groups
combined. Univariate analysis revealed that only a syncopal
episode was associated with increased incidence of both car-
diac death (p , 0.01) and sudden death (p , 0.05).
Symptoms. At the most recent evaluation of the 53 survi-
vors in Group 1, 34 patients were still completely asymptom-
atic, and the remaining 19 patients (36%, or about one-third)
had at least one newly developed cardiac symptom: cardiovas-
cular functional limitation in 10, chest pain in 9, and palpita-
Table 1. Comparison of Clinical Features at Presentation Between
Patients in Group 1 and in Group 2
Group 1
(n 5 58)
Group 2
(n 5 70) p Value
Mean age (year) 42.8 6 11.5 50.4 6 10.8 p , 0.01
(Range) (20–71) (23–74)
Mean follow-up period (year) 11.0 6 5.9 9.1 6 5.7 NS
Men (%) 95 81 p , 0.05
NYHA functional class
I 58 43 —
II 0 17 —
III 0 10 —
IV 0 0 —
Cardiac symptoms
Chest pain 0 19 —
Episode of syncope 0 8 —
Palpitations 0 19 —
Hypertension 17 27 NS
Family history of
HC 9 5 NS
Sudden death 12 7 NS
Medical therapy* 35 53 NS
*Medical therapy with beta-blockers, calcium channel antagonists, or both
for more than one-half of the follow-up period. Data are expressed as mean
value 6 SD or number of patients. ECG 5 electrocardiogram; HC 5 hypertro-
phic cardiomyopathy; NYHA 5 New York Heart Association.
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tion in 12. Of the 53 survivors in Group 2, except for the
aforementioned patient who had the cerebral vascular acci-
dent, 20 patients (38%) showed improvement after treatment
and were completely asymptomatic. None of the patients in
either group had newly developed syncopal episodes.
Discussion
To our knowledge, this study is the first to report a
prognosis for a relatively large population of completely
asymptomatic adult patients with HC during the long-term
follow-up period. The cardiac mortality rate of asymptomatic
patients (Group 1) was very low, significantly lower than that of
symptomatic patients (Group 2), and there was a dispropor-
tionately low incidence of sudden death.
Our asymptomatic patient group within the broad clinical
spectrum of HC. Despite numerous clinical investigations of
HC, the natural history of this disease has not been fully
defined, primarily because of substantial diversity with respect
to clinical presentation and prognosis. Our study is important
to asymptomatic patients who, owing to the absence of symp-
toms, are not likely to seek medical care. The aforementioned
distinct health care system, the clinical practice in Japan, and
our own policy for the management of patients with HC
afforded us the opportunity to investigate the clinical course
and long-term prognosis of this unique spectrum of HC. We
employed strict criteria for identifying Group 1 patients: only
those with no cardiac symptoms were included. Initial diagno-
sis of HC in Group 1 was suspected because of abnormal ECGs
and/or cardiac murmurs. We believe our asymptomatic patient
group is at the mild end of the disease spectrum for which
widely published data on HC are lacking.
Comparison with previous studies. Most prior clinical
studies on the natural history of HC have been based on
populations of highly selected patients from large tertiary
referral centers and have reported a poor prognosis due largely
to unexpected sudden cardiac death (3,5–7,29). The cardiac
mortality rates (approximately 2%) and the modes of death
observed in Group 2 were almost consistent with those in the
prior reports. However, Group 1 patients showed a benign
clinical course. Other recent clinical investigations on popula-
tions, which seem to present a benign HC spectrum, also
reported a favorable prognosis. Shapiro and Zezulka (13)
studied 39 patients over a 5-year period at a general hospital
and showed that mortality rates among these patients did not
differ from normal. Spirito et al. (12) followed 25 outpatients
for an average of 4 years and found no cases of cardiac death.
Kofflard et al. (14) followed a large clinic population of 113
patients for an average of 7 years and showed an annual
cardiac mortality rate of only 1%.
Indeed, these study populations seem to represent a rela-
tively mild disease spectrum compared with the referral
hospital-based populations in the prior studies. However, they
still provide few details concerning the asymptomatic patients
with HC. Hecht et al. (30) studied a subgroup of 31 middle-
Table 2. Comparison of ECG, Hemodynamic, Echocardiographic
and 24-h Holter ECG Data at Presentation Between Patients in
Group 1 and in Group 2
Group 1
(n 5 58)
Group 2
(n 5 70) p Value
ECG data (n 5 58) (n 5 70)
Atrial fibrillation 4 13 NS†
Established 1 1
Paroxysmal 3 12
Atrioventricular block 1 0
Intraventricular conduction delay 4 5 NS
SV1 1 RV5 (mV) 51.3 6 23.1 52.3 6 22.8 NS
Hemodynamic data (n 5 54) (n 5 64)
PAWP (mm Hg) 8.3 6 3.8 8.5 6 4.1 NS
LVEDP (mm Hg) 14.3 6 5.9 15.7 6 6.5 NS
Left ventricular ejection fraction 0.72 6 0.10 0.72 6 0.09 NS
Stroke volume index (ml/m2) 52 6 12 51 6 12 NS
Left ventricular outflow obstruction 14 17 NS
Echocardiographic data (n 5 52) (n 5 61)
Left atrial dimension index (mm/m2) 21.0 6 3.8 22.7 6 4.6 p , 0.05
Interventricular septal thickness (mm) 20.4 6 5.1 20.6 6 6.4 NS
Posterior wall thickness (mm) 12.9 6 3.0 13.0 6 2.8 NS
LVDdI (mm/m2) 26.6 6 4.1 26.7 6 3.9 NS
LVDsI (mm/m2) 16.2 6 3.1 16.1 6 3.5 NS
24-h Holter ECG data (n 5 38) (n 5 46)
Ventricular tachycardia 6 4 NS
PSVT 4 11 NS
†Actual p value 5 0.053. Data are expressed as mean value 6 SD or number
of patients. LVDdI 5 left ventricular end-diastolic cavity dimension index;
LVDsI 5 left ventricular end-systolic cavity dimension index; LVEDP 5 left
ventricular end-diastolic pressure; PAWP 5 pulmonary artery wedge pressure;
PSVT 5 paroxysmal supraventricular tachycardia; other abbreviations as in
Table 1.
Figure 1. Comparison of survival rates from cardiac death between
Groups 1 and 2.
Figure 2. Comparison of survival rates from sudden death between
Groups 1 and 2.
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aged asymptomatic patients with HC and followed them for an
average of 7 years. There were four sudden deaths, and these
investigators concluded that their asymptomatic patients re-
mained at enhanced risk of sudden death later in life. How-
ever, because their asymptomatic patients were defined only by
the absence of functional limitation (NYHA functional class I),
these patients seemed not to be completely asymptomatic by
our strict definition, and so would differ from our Group 1
patients.
Reasons for the benign prognosis observed in Group 1.
The infrequency of sudden cardiac death clearly contributed to
the favorable prognosis in our asymptomatic Group 1 patients,
and there are several possible explanations for these findings.
The major risk factors for sudden death in patients with HC
have been suggested to be clinical and arrhythmia-related
(3,5,8,10,31,32). These risk factors include younger age at
diagnosis (,14 years) (3,5), a family history of sudden death
due to HC (3,10,31), and a history of syncope (3,8,32). Our
study patients were confined to adult patients diagnosed with
HC at age $20 years, and did not include children who were
known to be at enhanced risk of sudden death without known
medical problems or symptoms (5,31). We also found that a
history of syncope was a major risk factor for sudden death and
had the most important impact on cardiac mortality. Regard-
ing a family history of sudden death due to HC, however, we
could not obtain reliable enough data to examine the relation
between such a family history and subsequent cardiac mortality
in this retrospective study. Thus, the benign prognosis in
Group 1 seemed to result from our patient age and the absence
of syncopal episodes.
Differences in clinical presentation between Groups 1 and
2. Group 2 patients were older and had larger LA dimensions
than did Group 1. The LV diastolic function is well known to
be impaired with aging (33,34). Symptomatic Group 2 patients
appeared to have more impaired LV diastolic function affected
by aging. Furthermore, it is expected that the more impaired
LV diastolic function would be reflected in higher LA pres-
sures, resulting in LA enlargement.
There were fewer females in Group 1 than in Group 2, and
there was an apparent predominance of males in the entire
study population, although HC is, in general, only a little more
common in men (12,14). This discrepancy may be partly due to
our patient selection process, which is affected by the health
care system and by clinical practice in Japan. Because the labor
participation rate of females is much lower than that of males
in Japan, females are less likely to undergo company-
sponsored health examinations that allow identification of the
asymptomatic patients with HC.
Study limitations. There were also few younger patients
(age at diagnosis ,20 years) to allow us to investigate a patient
population with a broad age range. Consequently, our obser-
vations should be interpreted with caution as they apply to a
largely adult study cohort with male predominance, as de-
scribed above.
Conclusions. In the present study, the cardiac mortality
rate of completely asymptomatic adult patients with HC was
very low, significantly lower than that of symptomatic patients,
and there was a disproportionately low incidence of sudden
death. Our findings may be useful in the management of
patients with HC surveyed in routine examinations, and helpful
in the investigation of the natural history of HC covering a
broad clinical spectrum.
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